PR Newswire: news distribution, targeting and monitoring
2014

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2012

Share with Twitter Share with LinkedIn

NEW YORK, Feb. 21, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2012

http://www.reportlinker.com/p01105509/Partnerships-Licensing-Investments-and-MA-Deals-and-Trends-in-Pharmaceuticals-–-Q4-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2012

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2012" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q4 2012. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2012 8
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2012 8
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2012 10
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2012 11
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2012 12
2.4.1 Abbott Completes Private Placement of Notes for $14.7 Billion 12
2.4.2 Roche Revises Offer Price to Acquire Illumina for Up to $8.2 Billion 12
2.4.3 UnitedHealth Group to Acquire 90% Stake in Amil Participacoes for $4.9 Billion 12
2.4.4 HCA Completes Public Offering of Notes for $3.5 Billion 13
2.4.5 HCP Completes Acquisition of Senior Housing Portfolio of Emeritus and Blackstone for $1.7 Billion 13
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 14
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q4 2012 14
3.1.1 Top M&A Deals in Q4 2012 15
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2011 - Q4 2012 16
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2012 17
3.2.1 Top Initial Public Offerings in Q4 2012 18
3.2.2 Top Secondary Offerings in Q4 2012 18
3.2.3 Top PIPE Deals in Q4 2012 18
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2011–Q4 2012 19
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2011 – Q4 2012 20
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q4 2012 21
3.3.1 Top Venture Financing Deals in Q4 2012 22
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2012 23
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2012 24
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2011 - Q4 2012 25
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 26
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 27
3.3.7 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2012 28
3.3.8 Top Private Equity Deals in Q4 2012 29
3.3.9 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2011 - Q4 2012 30
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2012 31
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2012 31
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2011 - Q4 2012 33
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 34
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2012 35
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2012 35
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2012 36
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2011 - Q4 2012 37
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2011 - Q4 2012 38
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2011 - Q4 2012 39
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2011 - Q4 2012 40
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2012 41
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2012 41
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2011 - Q4 2012 42
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2012 43
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2012 43
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2012 44
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2011 - Q4 2012 45
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2011 - Q4 2012 46
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2011 - Q4 2012 47
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2011 - Q4 2012 48
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2011 - Q4 2012 49
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 50
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q4 2011 - Q4 2012 50
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q4 2011 - Q4 2012 51
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2011 - Q4 2012 52
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2011 - Q4 2012 53
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q4 2011 - Q4 2012 54
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q4 2011 - Q4 2012 55
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2011 - Q4 2012 56
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 57
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2012 57
7.1.1 Oncology – Deals of the Quarter 58
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2012 59
7.2.1 Central Nervous System – Deals of the Quarter 60
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2012 62
7.3.1 Infectious Disease – Deals of the Quarter 63
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2012 64
7.4.1 Immunology – Deals of the Quarter 65
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2012 66
7.5.1 Metabolic Disorders – Deals of the Quarter 67
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2012 68
7.6.1 Cardiovascular – Deals of the Quarter 69
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2012 70
7.7.1 Gastrointestinal – Deals of the Quarter 71
7.8 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q4 2012 72
7.8.1 Ophthalmology – Deals of the Quarter 73
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2012 74
7.9.1 Respiratory – Deals of the Quarter 75
7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q4 2012 76
7.10.1 Dermatology – Deals of the Quarter 77
8 Deal Summary by Geography 78
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2012 78
8.1.1 North America – Deals of the Quarter 79
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2012 81
8.2.1 Europe – Deals of the Quarter 82
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2012 83
8.3.1 Asia-Pacific – Deals of the Quarter 84
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2012 85
8.4.1 Rest of the World – Deals of the Quarter 86
9 Pharmaceuticals & Healthcare, Global, Top Advisors 87
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 87
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 88
10 Appendix 89
11 Further Information 93
11.1 Methodology 93
11.2 About GlobalData 93
11.3 Contact Us 94
11.4 Disclosure information 94
11.5 Disclaimer 94

List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q4 2011 - Q4 2012 9
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q4 2012 11
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2012 12
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 – Q4 2012 15
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q4 2012 15
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q4 2011 - Q4 2012 16
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2011 - Q4 2012 17
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q4 2012 18
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q4 2012 18
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q4 2012 18
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2011–Q4 2012 19
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2011 - Q4 2012 20
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 21
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q4 2012 22
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q4 2012 24
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2011 - Q4 2012 25
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2012 – Q4 2012 26
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2011 – Q4 2012 27
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 – Q4 2012 28
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q4 2012 29
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2011 - Q4 2012 30
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 32
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 33
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2011 - Q4 2012 34
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 35
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2012 35
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q4 2012 36
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2011 - Q4 2012 37
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2011 - Q4 2012 39
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2011 - Q4 2012 40
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 41
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2011 - Q4 2012 42
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q4 2012 43
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q4 2012 43
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q4 2012 44
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 45
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q4 2011 - Q4 2012 46
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2011 - Q4 2012 48
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2011 - Q4 2012 49
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2011 - Q4 2012 50
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2011 - Q4 2012 51
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2011 - Q4 2012 52
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q4 2011 - Q4 2012 53
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2011 - Q4 2012 54
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q4 2011 - Q4 2012 55
Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2011 - Q4 2012 56
Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 58
Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 60
Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 62
Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 64
Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 67
Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 69
Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 70
Table 54: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 72
Table 55: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 74
Table 56: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 76
Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 79
Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 81
Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 84
Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 86
Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2012 - Q4 2012 87
Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2012 - Q4 2012 88
Table 63: Pharmaceuticals & Healthcare, Deals' Key Financials, Global Acquisition Deals, Q4 2011-Q4 2012 89

List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q4 2011 - Q4 2012 8
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q4 2012 10
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q4 2012 11
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q4 2011 - Q4 2012 14
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q4 2011 – Q4 2012 16
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 17
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q4 2011 – Q4 2012 20
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 21
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q4 2012 23
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q4 2012 24
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2011 - Q4 2012 25
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2012 – Q4 2012 26
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q4 2011 – Q4 2012 28
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2011 - Q4 2012 30
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 31
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 33
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2011 - Q4 2012 34
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2011 - Q4 2012 37
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2011 - Q4 2012 38
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2011 - Q4 2012 39
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2011 - Q4 2012 40
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 41
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2011 - Q4 2012 42
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 45
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2011 - Q4 2012 46
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q4 2011 - Q4 2012 47
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q4 2011 - Q4 2012 48
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2011 - Q4 2012 49
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2011 - Q4 2012 50
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2011 - Q4 2012 51
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2011 - Q4 2012 52
Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2011 – Q4 2012 53
Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2011 - Q4 2012 54
Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q4 2011 - Q4 2012 55
Figure 35: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2011 - Q4 2012 56
Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 57
Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 59
Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 62
Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 64
Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 66
Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 68
Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 70
Figure 43: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 72
Figure 44: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 74
Figure 45: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 76
Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 78
Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 81
Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 83
Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q4 2011 - Q4 2012 85
Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2012 - Q4 2012 87
Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2012 - Q4 2012 88

To order this report:
Investment_Banking Industry:
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2012

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release